In LEAP-004 study, up to 21% of patients experienced disease response, amongst them complete and partial responses [72], supporting the hypothesis that abrogation of pivotal intracellular pathways can reverse tumor resistance to anti-PD-1/PD-L1-based treatments. Here, PDCD1 is linked to neoplasm.